Hyperhomocysteinemia and its clinical implications - A short review

The global burden of disease indicates that cancers and vascular disease are responsible for the maximum morbidity and mortality. Hyperhomocysteinemia has been implicated as a risk marker/factor in both. Also measures to reduce circulating concentrations of homocysteine are fairly simple and without side effects. Yet such measures are not part of the management of these conditions. This review attempts to bring forth the necessity to include homocysteine-lowering therapy in the management of several disease conditions to reduce the morbidity and mortality.